The generative AI in healthcare market map
From protein design to synthetic patient data, we break down the categories of tech vendors bringing generative AI into the research and clinical settings.
From protein design to synthetic patient data, we break down the categories of tech vendors bringing generative AI into the research and clinical settings.
From mental health support features to ovarian health, we look at recent activity in key menopause care markets to identify trends in the space.
From molecule design to biomedical NLP, we break down 4 ways pharmaceutical companies can leverage generative AI — and the companies leading the way.
We mined Nvidia's investments and partnerships to discern the company’s strategic priorities in healthcare.
We mined Bayer’s acquisitions, investments, and partnerships to discern the company's strategic priorities.
Amid soaring interest in AI, this market map breaks down the AI companies helping pharma giants discover new drug targets and carry out clinical trials more efficiently.
From AI-powered liquid biopsies to clinical decision support, we break down the vendors aiming to transform cancer care, diagnosis, and treatment.
The Pharma AI Readiness Index assesses how prepared top pharmaceutical companies are to adopt and respond to rapidly evolving AI technologies.
From EHR-based patient recruitment to decentralized clinical trials, we break down the critical categories of vendors digitizing clinical trials.
Pharma companies are paying anywhere from $75K to $5M per year to acquire datasets that can speed up drug discovery, clinical trial design, and regulatory reporting.
Despite a slowdown in funding, the space has seen notable acquisitions and partnerships in 2023 involving BioNTech, Eli Lilly, and others. We assess the market's momentum.
We mined Amazon’s acquisitions, investments, and partnerships to discern the company’s strategic priorities in healthcare.
Over 20,000 founders applied to Y Combinator's Winter 2023 cohort. We analyze the 20 healthcare companies that made the cut.
From drug design to EHR documentation, we break down 7 ways health systems can leverage generative AI — and the vendors building these solutions.
From drug design to EHR documentation, we break down 7 ways health systems can leverage generative AI — and the vendors building these solutions.
We mined CB Insights business relationship data on Pfizer to highlight who it’s working with and distill its areas of strategic focus.
Despite strong tailwinds, psychedelics companies aren’t attracting investors like they used to.
We outline the market outlook for knowledge discovery in the life sciences industry — from investment trends and leading companies to recommendations for players in the space.
We outline the market outlook for cloud R&D software in the life sciences industry — from investment trends and leading companies to recommendations for players in the space.
We outline the market outlook for nature mining in the life sciences industry — from investment trends and leading companies to recommendations for the players in the space.
Tech giant Microsoft is growing its presence in the pharmaceutical space. We dig into its strategy here.
We mined Novartis’ acquisitions, investments, and partnerships to discern the company's strategic priorities.
Big tech is going after the $1T+ pharma market. Here’s how the tech titans are working to establish permanent places for themselves in the space through product launches, partnerships, M&A deals, and more.
We outline the market outlook for digital biomarkers for vital signs in the pharma and clinical research industry – from investment trends, to leading companies, to recommendations for the players in the space.
We outline the market outlook for patient data & analytics in the pharma and clinical research industry — from investment trends, to leading companies, to recommendations for players in the space.